Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and immunogenicity of MEDI7510 in older adults with respiratory syncytial virus infection; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• MEDI7510

Snippet

Sponsor: MedImmune LLC | Conditions: Respiratory Syncytial Virus (RSV) | Phase 1 | Status: COMPLETED | Results posted: 2018-02-19